Sentencing of former Par execs Desai, Bansal
Executive Summary
Ex-R&D Director Padam Bansal and former Quality Control Director Kanubhai Desai each sentenced to six months home detention and two years of probation by Baltimore federal court Judge John Hargrove March 19. Desai receives a $2,500 fine. In May 1992, Desai pled guilty to obstructing FDA's investigation of Par ("The Pink Sheet" May 18, 1992, T&G-15). Bansal admitted to lying to a federal grand jury in February 1992. Both Desai and Bansal have been cooperating with the Maryland U.S. Attorney's investigation regarding past ANDA falsification at the generics firm.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth